Formestane: an effective first-line endocrine treatment for advanced breast cancer

Nicoletta Zilembo; Emilio Bajetta; Cristina Noberasco; Roberto Buzzoni; Giovanni Vicario; Aldo Bono; Alberto Laffranchi; Giuseppa Biasi; Stella Dolci; Ettore Bichisao

doi:10.1007/BF01225692

Formestane: an effective first-line endocrine treatment for advanced breast cancer

Nicoletta Zilembo, Emilio Bajetta, Cristina Noberasco, Roberto Buzzoni, Giovanni Vicario, Aldo Bono, Alberto Laffranchi, Giuseppa Biasi, Stella Dolci, Ettore Bichisao

Research output: Contribution to journal › Article › peer-review

Abstract

Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To investigate the clinical activity and endocrinological effects of formestane as a first-line treatment, 52 patients were administered two different doses: 24 received 250 mg formestane and 28 received 500 mg formestane i.m. fortnightly. All of the patients had a performance status of 2 or less (ECOG scale), 34 (65%) had a disease-free interval of at least 2 years and 21 (40%) were both oestrogen-receptor- and progesterone-receptor-positive; 20 patients received hormone and 13 received chemotherapeutical adjuvant treatment. Objective responses were obtained in 8 patients in the 250-mg group (33%; 95% CI: 14%-52%) and in 13 patients in the 500-mg group (46%;, 95% CI.: 28%-64%). The median response duration in the two groups was respectively 11 and 12 months. E₂ serum levels of oestradiol had significantly (P

Original language	English
Pages (from-to)	378-382
Number of pages	5
Journal	Journal of Cancer Research and Clinical Oncology
Volume	121
Issue number	6
DOIs	https://doi.org/10.1007/BF01225692
Publication status	Published - Jun 1995

Keywords

Aromatase inhibitors
Breast neoplasm
Formestane
Hormonal treatment
Postmenopause

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/BF01225692

Fingerprint Dive into the research topics of 'Formestane: an effective first-line endocrine treatment for advanced breast cancer'. Together they form a unique fingerprint.

Cite this

Formestane : an effective first-line endocrine treatment for advanced breast cancer. / Zilembo, Nicoletta; Bajetta, Emilio; Noberasco, Cristina; Buzzoni, Roberto; Vicario, Giovanni; Bono, Aldo; Laffranchi, Alberto; Biasi, Giuseppa; Dolci, Stella; Bichisao, Ettore.

In: Journal of Cancer Research and Clinical Oncology, Vol. 121, No. 6, 06.1995, p. 378-382.

Research output: Contribution to journal › Article › peer-review

@article{ac829c22e97d4c0680042d1f7376af41,

title = "Formestane: an effective first-line endocrine treatment for advanced breast cancer",

abstract = "Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To investigate the clinical activity and endocrinological effects of formestane as a first-line treatment, 52 patients were administered two different doses: 24 received 250 mg formestane and 28 received 500 mg formestane i.m. fortnightly. All of the patients had a performance status of 2 or less (ECOG scale), 34 (65%) had a disease-free interval of at least 2 years and 21 (40%) were both oestrogen-receptor- and progesterone-receptor-positive; 20 patients received hormone and 13 received chemotherapeutical adjuvant treatment. Objective responses were obtained in 8 patients in the 250-mg group (33%; 95% CI: 14%-52%) and in 13 patients in the 500-mg group (46%;, 95% CI.: 28%-64%). The median response duration in the two groups was respectively 11 and 12 months. E2 serum levels of oestradiol had significantly (P",

keywords = "Aromatase inhibitors, Breast neoplasm, Formestane, Hormonal treatment, Postmenopause",

author = "Nicoletta Zilembo and Emilio Bajetta and Cristina Noberasco and Roberto Buzzoni and Giovanni Vicario and Aldo Bono and Alberto Laffranchi and Giuseppa Biasi and Stella Dolci and Ettore Bichisao",

year = "1995",

month = jun,

doi = "10.1007/BF01225692",

language = "English",

volume = "121",

pages = "378--382",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - Formestane

T2 - an effective first-line endocrine treatment for advanced breast cancer

AU - Zilembo, Nicoletta

AU - Bajetta, Emilio

AU - Noberasco, Cristina

AU - Buzzoni, Roberto

AU - Vicario, Giovanni

AU - Bono, Aldo

AU - Laffranchi, Alberto

AU - Biasi, Giuseppa

AU - Dolci, Stella

AU - Bichisao, Ettore

PY - 1995/6

Y1 - 1995/6

N2 - Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To investigate the clinical activity and endocrinological effects of formestane as a first-line treatment, 52 patients were administered two different doses: 24 received 250 mg formestane and 28 received 500 mg formestane i.m. fortnightly. All of the patients had a performance status of 2 or less (ECOG scale), 34 (65%) had a disease-free interval of at least 2 years and 21 (40%) were both oestrogen-receptor- and progesterone-receptor-positive; 20 patients received hormone and 13 received chemotherapeutical adjuvant treatment. Objective responses were obtained in 8 patients in the 250-mg group (33%; 95% CI: 14%-52%) and in 13 patients in the 500-mg group (46%;, 95% CI.: 28%-64%). The median response duration in the two groups was respectively 11 and 12 months. E2 serum levels of oestradiol had significantly (P

AB - Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To investigate the clinical activity and endocrinological effects of formestane as a first-line treatment, 52 patients were administered two different doses: 24 received 250 mg formestane and 28 received 500 mg formestane i.m. fortnightly. All of the patients had a performance status of 2 or less (ECOG scale), 34 (65%) had a disease-free interval of at least 2 years and 21 (40%) were both oestrogen-receptor- and progesterone-receptor-positive; 20 patients received hormone and 13 received chemotherapeutical adjuvant treatment. Objective responses were obtained in 8 patients in the 250-mg group (33%; 95% CI: 14%-52%) and in 13 patients in the 500-mg group (46%;, 95% CI.: 28%-64%). The median response duration in the two groups was respectively 11 and 12 months. E2 serum levels of oestradiol had significantly (P

KW - Aromatase inhibitors

KW - Breast neoplasm

KW - Formestane

KW - Hormonal treatment

KW - Postmenopause

UR - http://www.scopus.com/inward/record.url?scp=0029026232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029026232&partnerID=8YFLogxK

U2 - 10.1007/BF01225692

DO - 10.1007/BF01225692

M3 - Article

C2 - 7797604

AN - SCOPUS:0029026232

VL - 121

SP - 378

EP - 382

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 6

ER -